Additive hazards models with latent treatment effectiveness lag time

Research output: Contribution to journalArticle

Abstract

In many clinical trials for evaluating treatment efficacy, it is believed that there may exist latent treatment effectiveness lag times after which medical treatment procedure or chemical compound would be in full effect. In this paper, semiparametric regression models are proposed and studied for estimating the treatment effect accounting for such latent lag times. The new models take advantage of the invariant property of the additive hazards model in marginalising over an additive latent variable; parameters in the models are thus easily estimated and interpreted, while the flexibility of not having to specify the baseline hazard function is preserved. Monte Carlo simulation studies demonstrate the appropriateness of the proposed semiparametric estimation procedure. The methodology is applied to data collected in a randomised clinical trial, which evaluates the efficacy of biodegradable carmustine polymers for treatment of recurrent brain tumours.

Original languageEnglish (US)
Pages (from-to)917-931
Number of pages15
JournalBiometrika
Volume89
Issue number4
DOIs
StatePublished - 2002

Fingerprint

Additive Hazards Model
Time Lag
Proportional Hazards Models
Hazards
Carmustine
Brain Neoplasms
Efficacy
Polymers
Randomized Controlled Trials
Clinical Trials
Semiparametric Regression Model
Brain Tumor
Randomized Clinical Trial
Semiparametric Estimation
biodegradability
Biodegradable polymers
Chemical compounds
randomized clinical trials
Hazard Function
medical treatment

Keywords

  • Changepoint
  • Clinical trial
  • Cure model
  • Latent variable
  • Mixture model
  • Semiparametric model
  • Survival data

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Agricultural and Biological Sciences (miscellaneous)
  • Statistics and Probability
  • Mathematics(all)
  • Applied Mathematics

Cite this

Additive hazards models with latent treatment effectiveness lag time. / Chen, Y. Q.; Rohde, Charles A; Wang, Mei Cheng.

In: Biometrika, Vol. 89, No. 4, 2002, p. 917-931.

Research output: Contribution to journalArticle

@article{076f7d57ac2f492aa8716792e4fda09f,
title = "Additive hazards models with latent treatment effectiveness lag time",
abstract = "In many clinical trials for evaluating treatment efficacy, it is believed that there may exist latent treatment effectiveness lag times after which medical treatment procedure or chemical compound would be in full effect. In this paper, semiparametric regression models are proposed and studied for estimating the treatment effect accounting for such latent lag times. The new models take advantage of the invariant property of the additive hazards model in marginalising over an additive latent variable; parameters in the models are thus easily estimated and interpreted, while the flexibility of not having to specify the baseline hazard function is preserved. Monte Carlo simulation studies demonstrate the appropriateness of the proposed semiparametric estimation procedure. The methodology is applied to data collected in a randomised clinical trial, which evaluates the efficacy of biodegradable carmustine polymers for treatment of recurrent brain tumours.",
keywords = "Changepoint, Clinical trial, Cure model, Latent variable, Mixture model, Semiparametric model, Survival data",
author = "Chen, {Y. Q.} and Rohde, {Charles A} and Wang, {Mei Cheng}",
year = "2002",
doi = "10.1093/biomet/89.4.917",
language = "English (US)",
volume = "89",
pages = "917--931",
journal = "Biometrika",
issn = "0006-3444",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Additive hazards models with latent treatment effectiveness lag time

AU - Chen, Y. Q.

AU - Rohde, Charles A

AU - Wang, Mei Cheng

PY - 2002

Y1 - 2002

N2 - In many clinical trials for evaluating treatment efficacy, it is believed that there may exist latent treatment effectiveness lag times after which medical treatment procedure or chemical compound would be in full effect. In this paper, semiparametric regression models are proposed and studied for estimating the treatment effect accounting for such latent lag times. The new models take advantage of the invariant property of the additive hazards model in marginalising over an additive latent variable; parameters in the models are thus easily estimated and interpreted, while the flexibility of not having to specify the baseline hazard function is preserved. Monte Carlo simulation studies demonstrate the appropriateness of the proposed semiparametric estimation procedure. The methodology is applied to data collected in a randomised clinical trial, which evaluates the efficacy of biodegradable carmustine polymers for treatment of recurrent brain tumours.

AB - In many clinical trials for evaluating treatment efficacy, it is believed that there may exist latent treatment effectiveness lag times after which medical treatment procedure or chemical compound would be in full effect. In this paper, semiparametric regression models are proposed and studied for estimating the treatment effect accounting for such latent lag times. The new models take advantage of the invariant property of the additive hazards model in marginalising over an additive latent variable; parameters in the models are thus easily estimated and interpreted, while the flexibility of not having to specify the baseline hazard function is preserved. Monte Carlo simulation studies demonstrate the appropriateness of the proposed semiparametric estimation procedure. The methodology is applied to data collected in a randomised clinical trial, which evaluates the efficacy of biodegradable carmustine polymers for treatment of recurrent brain tumours.

KW - Changepoint

KW - Clinical trial

KW - Cure model

KW - Latent variable

KW - Mixture model

KW - Semiparametric model

KW - Survival data

UR - http://www.scopus.com/inward/record.url?scp=18444417022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18444417022&partnerID=8YFLogxK

U2 - 10.1093/biomet/89.4.917

DO - 10.1093/biomet/89.4.917

M3 - Article

AN - SCOPUS:18444417022

VL - 89

SP - 917

EP - 931

JO - Biometrika

JF - Biometrika

SN - 0006-3444

IS - 4

ER -